28
Therapeutic Targeting of CD45 by Novel Agents to Immunotherapy Non-responders Tumors
Ramot At Tel Aviv University
Peptide
Oncology
Hit To Lead or Lead Optimization
Unmet Needs
TNBC is an aggressive type of cancer, often diagnosed at a more advanced stage which affects younger women and lacks targeted therapies. Despite that TNBC can display immunogenic features, immunotherapy strategies have resulted in disappointing results, underscoring the need to optimize their use in TNBC. Resistance to immuno check point inhibitors remains a major hurdle to overcome, with a major need to explore novel immunotherapy strategies.
Our Solution
We develop small molecules and peptides binding to a specific epitope on CD45 receptor which reverses immunosuppression exerted by TNBC cells. Those novel agents can be combined with existing therapies for the treatment of immunotherapy non-responders tumors.
Applications and Status
• Specific binding to CD45 on immunosuppressed cells averts many of the immune related adverse events
• Peptides and small molecules display low toxicity, fewer side effects and minimal drug-drug interaction
• Easily and inexpensively produced
• MOA is complementary to that of many immune checkpoint inhibitors and other cancer drugs
RAITER Annat
PCT-IL2020-050193 (2020.02.21)
Patent Family: US, EP
• "A novel role for an old target: CD45 for breast cancer immunotherapy". Raiter, A. et al. OncoImmunology 2021, 10(1)
• "TNBC-derived Gal3BP/Gal3 complex induces immunosuppression through CD45 receptor". Raiter, A. et al. OncoImmunology 2023, 12:1, DOI: 10.1080/2162402X.2023.2246322
